



# Investment Vehicle: **GENESIS Tech Transfer Boost**

**TEASER**

June 2023





# Executive Summary

## 01

GENESIS Tech Transfer Boost is **an investment vehicle** created in 2022 and managed by the consulting firm GENESIS Biomed, with the aim of detecting and investing in **early-stage projects** in the biomedical sector, whether from hospitals or academic institutes.

## 02

The founding partners are **GENESIS Biomed, FI Group** and **Crowd4Ventures**, which are committing a total of **€1M** the next 4 years. In addition, the total size of the vehicle can be increased through the current partners and the incorporation of new ones.

## 03

The creation of the investment vehicle will allow to identify projects in **an solid ecosystem**. In addition, they will be accompanied and managed from the early stages of the project, **accelerating its arrival to the market**.

## 04

The vehicle is positioned in the incubation area, targeting *early-stage* projects. It is **agnostic** in the biomedical field, investing in projects **that fit into the vehicle's life cycle, in terms of medtech, diagnostic, biotech and digital**.

## 05

**Tickets ranging from €25,000 to €100,000** will be invested, depending on the nature of each project and its needs. The vehicle is allowed to invest in pre-foundation phase of the selected projects.

## 06

**GENESIS Biomed** has validated the vehicle's value proposition and investment model through a first vehicle, GENESIS Ventures I, which has invested in **13 projects** and has a portfolio valuation of **x3.37** factor to date.



# Introduction

The **main objective** of the vehicle is to provide financial support to projects or companies, With the aim of accompanying these **high impact** projects to achieve **effective transfer** to the National Health System.

## What do we propose?

- 1 **Creation of a technology transfer investment vehicle** for high-impact *early-stage* research projects from hospitals or academic institutes, always in the health sector.
- 2 **Acceleration** in the development of **projects** and reaching valuable milestones.
- 3 **Follow-up and support in attracting a first round** of investment involving other private equity vehicles.

## How will we achieve this?

- 1 **Close collaboration and synergy with leading institutes and organisations in the sector**
- 2 **Follow up and management of the project** from the early stages and during the project's track record. **Support in the development of the projects.**
- 3 Careful **identification and selection of projects and companies** to be financed with a model and **methodology validated** in GENESIS Ventures I.


## What are the advantages?

- 1 Identify projects in a **solid ecosystem** in order to **accelerate their go-to-market.**
- 2 **Increased attractiveness** for **potential future capital increases** with the future participation of other **venture funds.**
- 3 **Benefit from GENESIS Biomed's experience** as manager and investor in *early-stage* projects/companies. GENESIS Ventures I has participated in 13 companies.




# Life Cycle and Portfolio Management

Acceleration of the project, speeding up its development and reaching the most important valuable milestones.






# Structure of the Investment Vehicle (1/2)





# Structure of the Investment Vehicle (2/2)





# Management Team



## **Josep Lluís Falcó**

Managing partner & CEO

In 2017 he founded GENESIS Biomed, a business consultancy focused on supporting projects in the health sector, helping entrepreneurs to bring their innovation to the market. Josep Lluís has 22 years of experience in the biomedical sector, has founded 4 companies and is currently a board member of 3 start-ups. In addition, in the last 4 years he has participated in 18 private fundraising processes and has contributed to raising more than 65 million euros for GENESIS Biomed's clients.



## **Natalia de la Figuera**

Managing partner & COO

She has more than 20 years of professional experience in the biomedical sector, having worked as a researcher and as technician in the regulatory field for large pharmaceutical companies.

Her professional experience has been mainly focused on the field of the pharmaceutical company in different aspects (Project Management, Regulatory Affairs R&D, quality among others).



## **Agustí Soler**

CFO

Agustí Soler has more than 20 years of experience in the field of venture capital and start-ups, as well as in corporate finance. He has worked for more than 10 years as an Accounts Auditor, for top tier companies, in the field of venture capital and startups and more than 7 years holding management positions in Finance departments. He has been CFO and Operations Director at Inveready for 7 years and is currently interim CFO at OXOLIFE, CORNEA and CORIFY and joins GENESIS Tech Transfer Boost as CFO.



# Investment Analyst Team



## Berta Tenas

Investment Analyst

Berta has experience in the research field, having worked at the Department of Chemistry of the UAB (Barcelona), at the Neurosciences Research Area of the VHIR (Barcelona) and at Sciensano: the Belgian National Institute of Public Health (Brussels). After her degree, Berta completed an MSc in Technology and Business Management to discover another field of biotechnology, the business sector. Afterwards, Berta joined GENESIS Biomed in January 2021. During these years working in consulting, she has gained experience in the development of strategic plans (both for companies and institutions), in the development of business plans, in providing support in technology transfer, among other skills. Berta also works in GENESIS Biomed's investment vehicle, GENESIS Tech Transfer Boost, where she analyzes the most attractive investment opportunities for the healthcare sector.



## Rafael Sáenz de Tejada


Investment Analyst

Pharmacist with experience in business & investment analytics. During his undergraduate studies he gained scientific knowledge, organizational, and communicational skills. His Master's, taught through the Case Method, allowed him to think more critically, become adaptable when facing diverse situations, be customer-focused and work thoroughly to achieve his goals. Working for a Biotech consulting firm, has allowed Rafael to acquire decisive knowledge within the business management chain, business plan, patient support and strong dynamic skills. His final master's degree project was focused on molecular farming. He joined GENESIS Biomed in January 2023. Eager to improve people's health by combining his scientific and business knowledge.





# Track record Portfolio GENESIS Ventures I



- Divestment
- Next round already closed
- Next round in negotiation
- Non-continuous

<p><b>QualityPharma</b></p> <p>Spinoff Karolinska</p> <p>New clinical decision support system</p> <p><b>Ticket: 100.000€</b></p>	<p><b>limnopharma</b></p> <p>Spinoff CSIC</p> <p>New therapy for retinitis pigmentosa</p> <p><b>Ticket: 125.000€</b></p>	<p><b>ADmit THERAPEUTICS</b></p> <p>Spinoff IDIBELL</p> <p>IVD early detection of Alzheimer's disease</p> <p><b>Ticket: 125.000€</b></p>	<p><b>MOWOOT</b></p> <p>Start-up</p> <p>New device for spinal cord injury &amp; chronic constipation</p> <p><b>Ticket: 100.000€</b></p>	<p><b>EndoLipiD Therapeutics</b> Solutions for ectopic fat</p> <p>Spinoff VHIR</p> <p>New therapy for obesity and fatty liver disease</p> <p><b>Ticket: 100.000€</b></p>	<p><b>AORTYX</b></p> <p>Spinoff IQS - Clínic</p> <p>New device for aortic aneurysm treatment</p> <p><b>Ticket: 75.000€</b></p>	
<p><b>ELEM</b></p> <p>Spinoff BSC-UPC</p> <p>New in silico organ virtualization</p> <p><b>Ticket: 75.000€</b></p>	<p><b>CreatSens</b></p> <p>Spinoff URV</p> <p>New IVD for chronic kidney disease</p> <p><b>Ticket: 100.000€</b></p>	<p><b>able human motion</b></p> <p>Spinoff UPC</p> <p>New exoskeleton for spinal cord injury and stroke</p> <p><b>Ticket: 50.000€</b></p>	<p><b>DROPLITE</b></p> <p>Spinoff ICFO</p> <p>IVD for hormone detection in in vitro fertilization</p> <p><b>Ticket: 50.000€</b></p>	<p><b>THYTECH</b></p> <p>Spinoff IISGM</p> <p>Development of new ThyTreg cell therapy for autoimmune diseases</p> <p><b>Ticket: 40.000€</b></p>	<p><b>NEUROHEAL</b></p> <p>Spinoff UAB</p> <p>New therapy for neuroregeneration</p> <p><b>Ticket: 150.000€</b></p>	<p><b>Aptamer</b></p> <p>Spinoff IRYCIS</p> <p>New aptamer for breast cancer treatment</p> <p><b>Ticket: 50.000€</b></p>

At GENESIS Ventures I the valorization factor is **x3.37** from the initial investment (< 4 years).



# Some success stories from our track record

## Our track record as consultants:

- More than 200 projects completed.
- Over €65m raised.
- 18 closed funding rounds. Some of them (in blue) ITEMAS projects:



**January 2022:** EIT Health project award of €2.5m with a direct investment to Corify of €0.5m.  
**February 2021:** Closing of €2.35m private investment round (Capital Cell) and Clave Mondragon.



**January 2021:** €8.6m in this round through a convertible loan round of €25m.  
**December 2020:** Closing round of €11.4m through private investors. Record since 2017 of €15.9m.



**December 2020:** Closing of €0.87m private investment round (Capital Cell).



**May 2020:** Closing of €5m round through private investment (Inveready, Capital Cell, CDTI and Family Offices).



**May 2017:** closing of €15m private investment round (Ysios, Omega, Innogest and Banc Sabadell).



**October 2017:** Closing of €3.1m private investment round (Caixa Capital Risk and Healthequity).



**May 2017:** Closing of €4.5m private investment round (Caixa Capital Risk and Inveready).

## Our indicators as investors in GENESIS Ventures I:

- **13** projects invested. 7 projects have risen funds after our investment and 3 of them are under negotiation, 1 has been divested and 2 have been discontinued.
- **15 million received** in the four years following GENESIS Ventures' investment in the companies allowing a portfolio revaluation of €1.2m (offering a factor x3.37).



Investment 2019

**January 2022:** Closing of €0.97m round through Capital Cell.  
**July 2020:** Closing of €0.8m investment through EIT Health.  
**March 2019:** Closing round of €0.44m through Capital Cell.



Investment 2019

**December 2021:** Closing of €0.49m round through Capital Cell.



Investment 2018

**December 2021:** Closing of €1.3m round through Capital Cell.



Investment 2018

**April 2021:** Closing of €0.78m round through private investors and €3.4m EIC Accelerator.



Investment 2019

**April 2021:** Closing of €2.4m round through Capital Cell and €2.5m EIC Accelerator.



Investment 2019

**July 2020:** €0.3m Caixa Impulse Consolidate.  
**January 2020:** €0.5m directly from EIT Health in a project with a budget of more than € 3m.



Investment 2019

**August 2020:** a project by CreatSens Health, CKDSens, has received €1.3m in funding from the RETOS programme.



# Our current client portfolio (1/5): Startups and Spinoff

## Spin-off and start-up companies



# Our current client portfolio (2/5): Academic, research and technology centers

## Academia & Research

**barcelonaBeta**

BRAIN RESEARCH CENTER



POLITÉCNICA



Centre for Genomic Regulation



Parc Científic de Barcelona  
UNIVERSITAT DE BARCELONA



Bosch i Gimpera  
UNIVERSITAT DE BARCELONA



INSTITUTE FOR RESEARCH IN BIOMEDICINE



ICN2  
Institut Català de Nanociència i Nanotecnologia



CIC bioGUNE  
CENTER FOR COOPERATIVE RESEARCH IN BIOSCIENCES



Fundación Universidad Autónoma de Madrid



LEITAT  
managing your technologies member of TECNIO



MEMBER OF BASQUE RESEARCH & TECHNOLOGY ALLIANCE



CIC biomaGUNE  
CENTER FOR COOPERATIVE RESEARCH IN BIOMATERIALS



xartecsalut



eurecat  
Centre Tecnològic de Catalunya



ICFO



Universitat Autònoma de Barcelona



iQAC CSIC  
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS



IQS  
PERSONA CIENCIA EMPRESA  
UNIVERSITAT RAMON LLULL



IQS  
PERSONA CIENCIA EMPRESA  
EXECUTIVE EDUCATION



UNIVERSITAT ROVIRA I VIRGILI



Fundación General CSIC



Inndromeda



cnag  
centre nacional d'anàlisi genòmica  
centro nacional de análisis genómico



Universidad de Navarra



ICMAB  
INSTITUT DE CIÈNCIA DE MATERIALS DE BARCELONA



UNIVERSITAT DE BARCELONA



UNIVERSITAT POLITÈCNICA DE VALÈNCIA



IBEC  
Institute for Bioengineering of Catalonia



BSC  
Barcelona Supercomputing Center  
Centro Nacional de Supercomputación



idm



nonbiosis



ISABIAL  
INSTITUTO DE INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE ALICANTE



EXCELENCIA SEVERO OCHOA CSIC  
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS



Universidad de Granada



UNIVERSITAT DE VALÈNCIA



UNIVERSIDAD DE MURCIA



ICIQ



upf. Universitat Pompeu Fabra Barcelona



ciber-66n  
Biomedical Research Networking Center  
Bioengineering, Biomaterials, Nanomedicine



UNIVERSITAT MIGUEL HERNÁNDEZ



KATHOLIEKE UNIVERSITEIT LEUVEN



ibbttec



umec



UNIVERSITY OF LISBOA



The University of Dublin



UNIVERSITY OF COPENHAGEN



Karolinska Institutet



ICCC



Fundació Universitat Empresa de les Illes Balears



CSIC  
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS



UNIVERSIDADE DE COIMBRA



University of Cyprus



# Our current client portfolio (3/5): Hospitals and health research institutions

## Healthcare





# Our current client portfolio (4/5): Investors, large companies and institutions

## Investors



## Big & mid-size companies



## Institutional





# Our current client portfolio (5/5): EU-funded projects in which we participate



**SAVE-COR**   
Stratification of Atrial and Ventricular Arrhythmias based on Non-invasive Electrocardiographic Imaging

**RETINAREADRISK**

 **able**  
human motion

**FiSPlat** 

 **HARMONICS**

 **AF-FINE**  
Artificial intelligence driven platform for atrial fibrillation stratification

**CKDSens**® 

 **FACET SYSTEM**

**INVESTOR NETWORK** 

**ProVerum** 

 **HOOP**

**POSITIVE** 

**QuickStitch**  
Innovation 

**miniQ** 

**Walk TEST** 



**barcelonaβeta**  
BRAIN RESEARCH CENTER

**EVERAI** MEDICAL TECHNOLOGIES



**LIVER SCREEN**

**Interreg Sudoe**   
CARDIOPATCH  
European Regional Development Fund

**Recognised** 

 **MJN**  
Quality life for everybody



BARCELONA · MADRID · VALENCIA

©GENESIS Biomed

Barcelona Office:

Barcelona Science Park  
Tower I, offices 3B01-03-05-06  
Baldiri Reixac 4-8  
08028 Barcelona  
+34 93 403 58 53

Madrid Office:

Velázquez 25, 2º A  
28001 Madrid

Valencia Office:

Travesía 15E  
46024 Valencia

[contact@genesis-biomed.com](mailto:contact@genesis-biomed.com)

GENESIS Biomed is member of:



Fins a 30/12/2030